

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: **94610012.0**

(22) Date of filing: **11.03.94**

(51) Int. Cl.⁵: **A61K 31/415**, A61K 31/44,
 C07D 401/10, C07D 405/14,
 C07D 403/10, C07D 235/06,
 C07D 487/06, C07D 471/06,
 C07D 405/00, C07D 413/00,
 C07D 401/00, C07D 513/04

(30) Priority: **24.03.93 DK 337/93**
21.09.93 DK 1055/93

(43) Date of publication of application:
28.09.94 Bulletin 94/39

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: **NEUROSEARCH A/S**
Smedeland 26B
DK-2600 Glostrup (DK)


(71) Applicant: **MEIJI SEIKA KAISHA LTD.**
4-16 Kyobashi 2-chome
Chuo-ku Tokyo 104 (JP)

(72) Inventor: **Axelsson, Oskar**
Stora Kvarngatan 5-604
S-211 27 Malmö (SE)
 Inventor: **Teuber, Lene**
Anemonevej 32
DK-3500 Vaerlose (DK)
 Inventor: **Wätjen, Frank**
Afaldet 22
DK-2730 Herlev (DK)



(74) Representative: **Wulff, Peter Samuel**
c/o NeuroSearch A/S,
Smedeland 26B
DK-2600 Glostrup (DK)

(54) **Benzimidazole useful in the treatment of central nervous system disorders.**


(57) **Compounds having the formula:**



or a pharmaceutically acceptable salt thereof
 wherein
 R³ is



or



are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

This invention relates to novel benzimidazole compounds, pharmaceutical compositions thereof, a method of treating therewith, and to a method of preparing such benzimidazole compounds. The novel compounds are useful in the treatment of central nervous system diseases and disorders, and for example in the treatment of convulsions, anxiety, sleep disorders, and memory disorders.

Background of the invention

It is a well known fact, that specific sites in the central nervous system (the CNS) of a living animal body, including a human, exhibit highly specific binding for benzodiazepines such as for example diazepam. These binding sites are named benzodiazepine receptors. Lately, several subtypes of such benzodiazepine receptors have been isolated and described by techniques of modern molecular biology.

Numerous compounds belonging to different series of compounds having affinity for the benzodiazepine receptors have been synthesized during the last three decades. However, although the benzodiazepine receptor sites still are considered as very attractive biological sites for interfering with the CNS to treat various disorders and diseases, then nearly all previously synthesized compounds acting at these receptor sites have failed during clinical development because of unacceptable side effects.

Therefore, there is still a large need to identify novel compounds interacting with the benzodiazepine receptors.

Object of the invention

It is an object of the present invention to provide novel benzimidazole compounds and pharmaceutically-acceptable acid addition salts thereof, which are useful for the treatment of central nervous system disorders, diseases or ailments, and especially for the treatment of convulsions, anxiety, sleep disorders, and memory disorders.


Another object of the present invention is to provide pharmaceutical compositions comprising the novel benzimidazole compounds being useful for above purposes.

Still another object of the present invention is to provide a novel method of treating with the novel benzimidazole compounds.


Additional objects will be obvious from the following description, and others will be obvious to one skilled in the art.

Summary of the Invention

The invention then, *inter alia*, comprises the following, alone or in combination:
A compound having the formula:



or a pharmaceutically acceptable salt thereof
wherein
R³ is



wherein

X is N; or C-R' wherein R' is hydrogen or together with R⁴ forms a -(NR¹¹)_m-C(=O)-, -(NR¹¹)_m-CHOH-, or a -N=C- bridge wherein R¹¹ is hydrogen or alkyl and m is 0 or 1;


one of A, B, C, and D is N and the others are CH₂;

one of E, F, G, and K is N-R'' wherein R'' is hydrogen or alkyl and the others of E, F, G, and K are CH₂;

R⁶ and R⁷ are independently hydrogen; halogen; amino; nitro; cyano; acylamino; trifluoromethyl; alkyl; alkoxy; COO-alkyl; acyl; CH=NOH, CH=NO-alkyl; CH=N-NH-(C=O)-NH₂; phenyl which may be substituted one or more times with alkyl, nitro, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁶ and R⁷ together forms a (CH₂)_a-(Z)_b-(C=Y)_c-(Z')_d-(CH₂)_e bridge wherein each of Z and Z' independently are O, S, or NR''' wherein R''' is hydrogen or alkyl, Y is O or H₂, a and e are each independently 0, 1, 2, or 3 and b, c, and d are each independently 0 or 1 provided that the sum of a, b, c, d, and e is not larger than 6; or R⁶ and R⁷ together forms a -CH=CH-CH=N-, -CH=CH-N=CH-, -CH=N-CH=CH-, -N=CH-CH=CH-, or =N-S-N= bridge;

R⁴ is hydrogen; amino; nitro; cyano; halogen; acylamino; phenyl which may be substituted one or more times with alkyl, amino, halogen, or CF₃; aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁴ together with R' forms a -(NR¹¹)_m-C(=O)-, -(NR¹¹)_m-CHOH-, or a -N=C- bridge wherein R¹¹ is hydrogen or alkyl, and m is 1;

R¹¹ is phenyl which may be substituted one or more times with alkyl, halogen, or CF₃; benzimidazolyl which may be substituted one or more times with alkyl, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃, amino, nitro, cyano, acylamino, trifluoromethyl; alkoxy; or acyl; provided that at least one of R⁶ and R⁷ is other than hydrogen, and a compound as above wherein R⁴ is hydrogen and R³ is



wherein R¹¹ is pyridyl, and

a compound as above, which is

1-[3-(3-pyridyl)-phenyl]-5-methylaldoximo-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-(2-furanyl)-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,

1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,

1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,

1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,


1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or

4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-*ab*][1,4]benzodiazepine,

or a pharmaceutically acceptable salt thereof, and


a pharmaceutical composition comprising an effective amount of a compound as any above, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent, and

the use of a compound having the formula:



or a pharmaceutically acceptable salt thereof
wherein

R³ is



wherein

X is N; or C-R' wherein R' is hydrogen or together with R⁴ forms a $-(NR^{11})_m-C(=O)-$, $-(NR^{11})_m-CHOH-$, or a $-N=C-$ bridge wherein R¹¹ is hydrogen or alkyl and m is 0 or 1;

one of A, B, C, and D is N and the others are CH;

one of E, F, G, and K is N-R'' wherein R'' is hydrogen or alkyl and the others of E, F, G, and K are CH₂;

R⁶ and R⁷ are independently hydrogen; halogen; amino; nitro; cyano; acylamino; trifluoromethyl; alkyl; alkoxy; COO-alkyl; acyl; CH=NOH, CH=NO-alkyl; CH=N-NH-(C=O)-NH₂; phenyl which may be substituted one or more times with alkyl, nitro, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁶ and R⁷ together forms a $(CH_2)_a-(Z)_b-(C=Y)_c-(Z')_d-(CH_2)_e$ bridge wherein each of Z and Z' independently are O, S, or NR''' wherein R''' is hydrogen or alkyl, Y is O or H₂, a and e are each independently 0, 1, 2, or 3 and b, c, and d are each independently 0 or 1 provided that the sum of a, b, c, d, and e is not larger than 6; or R⁶ and R⁷ together forms a $-CH=CH-CH=N-$, $-CH=CH-N=CH-$, $-CH=N-CH=CH-$, $-N=CH-CH=CH-$, or $=N-S-N=$ bridge;

R⁴ is hydrogen; amino; nitro; cyano; halogen; acylamino; phenyl which may be substituted one or more times with alkyl, amino, halogen, or CF₃; aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁴ together with R' forms a $-(NR^{11})_m-C(=O)-$, $-(NR^{11})_m-CHOH-$, or a $-N=C-$ bridge wherein R¹¹ is hydrogen or alkyl, and m is 1;

R¹¹ is halogen; amino; nitro; cyano; COO-alkyl; acylamino; CF₃; alkyl; alkoxy; morpholinyl; phenyl which may be substituted one or more times with alkyl, halogen, or CF₃; benzimidazolyl which may be substituted one or more times with alkyl, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃, amino, nitro, cyano, acylamino, trifluoromethyl; alkoxy; or acyl, for the manufacture of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which is responsive to modulation of the benzodiazepine receptor of the central nervous system of such a living animal body, including a human, and

the use of a compound as second above for the manufacture of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which is responsive to modulation of the benzodiazepine receptor of the central nervous system of such a living animal body, including a human, and

the use of a compound as any above for the manufacture of a medicament for the treatment of anxiety, sleep disorders, memory disorders, epilepsy or any other convulsive disorder of a living animal body, including a human, and

the use as any above, wherein the compound employed is

1-[3-(3-pyridyl)-phenyl]-5-methylaldoximo-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-5-(2-furanyl)-benzimidazole,


1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,

1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or
 4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-ab][1,4]benzodiazepine,
 or a pharmaceutically-acceptable addition salt thereof, and
 a method of preparing a compound as any above, comprising the step of reacting a compound having the formula



wherein R³, R⁴, R⁶ and R⁷ have the meanings set forth in claim 1, with formic acid or a reactive derivative thereof, and

a method as above wherein

1-[3-(3-pyridyl)-phenyl]-5-methylaldoximo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5(2-furanyl)-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or
 4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-ab][1,4]benzodiazepine,
 or a pharmaceutically-acceptable addition salt thereof, is prepared.

Halogen is fluorine, chlorine, bromine, or iodine.

Alkyl means a straight chain or branched chain of from one to eight carbon atoms or cyclic alkyl of from three to seven carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; methyl, ethyl, propyl, isopropyl and *t*-butyl are preferred groups.

Alkoxy means O-alkyl, wherein alkyl is as defined above.

Acyl means (C=O)-H or (C=O)-alkyl, wherein alkyl is as defined above.

Alkylene is an alkylene group of from one to eight carbon atoms which may be straight or branched.

Acylamino is acyl-NH wherein acyl is as defined above.

Amino is NH₂ or NH-alkyl or N-(alkyl)₂, wherein alkyl is as defined above.

Aryl is a 5- or 6-membered heterocyclic monocyclic group. Such an aryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl, 1,2,5-thiadiazol-3-yl, 1,2,5-thiadiazol-4-yl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl.

Examples of pharmaceutically-acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulphate, citrate, lactate, tartrate,

maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2-sulphonate, salicylate and the acetate for example.

Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts. Such salts are formed by procedures well known in the art.

Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

Some of the compounds of the present invention exist in (+) and (-) forms as well as in racemic forms. Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or l- (tartrates, mandelates, or camphorsulfonate) salts for example. The compounds of the instant invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.

Additional methods for the resolution of optical isomers, known to those skilled in the art may be used, and will be apparent to the average skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

Starting materials for the processes described in the present application are known or can be prepared by known processes from commercially available chemicals.

The products of the reactions described herein are isolated by conventional means such as extraction, crystallization, distillation, chromatography, and the like.

Biology

4-aminobutyric acid (GABA) is the major inhibitory neurotransmitter and has been shown to act throughout both the central and peripheral nervous system. At present two types of GABA receptors are known, the GABA_A and the GABA_B receptors. Recent molecular biology has demonstrated that the GABA_A receptors can be subdivided into numerous subreceptors consistent with the selective and or partial pharmacological effects observed with certain benzodiazepine receptor ligands as opposed to the unselective effects observed for the classical benzodiazepine receptor ligands such as for example diazepam. Activation of GABA receptors leads to alternations in membrane potential (hyperpolarization). The GABA_A receptors are associated with chloride influx through its associated and integrated chloride channel, whereas GABA_B receptor activation indirectly alters potassium and calcium channels as well as modifies second messenger production. The GABA_A recognition sites can be activated by GABA, muscimol; and isoguvacine for example, but not by GABA_B agonists such as for example baclofen. The modulatory GABA_A recognition site at the benzodiazepine receptor sites can be selectively radiolabelled with ³H-flunitrazepam. The affinity of various potential ligands for the benzodiazepine receptor sites can thus be evaluated by estimating the ability of test compounds to displace ³H-flunitrazepam.

Method

Tissue preparations are performed at zero to four degrees celcius. Cerebral cortex from male Wistar rats (150-200g) is homogenized in 2 times 10 ml Tris-HCl, 30mM at pH 7.4. The resulting suspension is centrifuged at 40,000 g for 15 minutes. The pellet is washed three times with buffer, centrifuged at two degrees celcius at 40,000 g for ten minutes. The washed pellet is homogenized in 2 times 10 ml of buffer and is thereafter incubated on a water bath at 37°C for 30 minutes and is thereafter centrifuged at 40,000 g for 10 minutes. The pellet is then homogenized with buffer and is centrifuged at 0°C for 10 minutes at 40,000 g. The final pellet is resuspended in 30 ml buffer and the preparation may thereafter be stored at -20°C. In the test situation the membrane preparation is thawed and centrifuged at 2°C for ten minutes at 48,000 g. The pellet is then washed two times with 2 times 10 ml 50 mM Tris-citrate at pH 7.1 using an Ultra-Turrax homogenizer and centrifuged at 48,000 g for 10 minutes. The hereby obtained pellet is resuspended in 50 mM Tris-citrate at pH 7.1, 500 ml buffer per gram of original tissue, and is then used for binding assays. Aliquots of 0.5 ml tissue is added to

0.025 ml of ^3H -flunitrazepam, final concentration of 1nM, and is mixed and incubated for 40 minutes at 2°C. Non-specific binding is determined using clonazepam, at 100ng/ml final concentration. After incubation 5 ml of icecold buffer is added to the samples and these are poured directly onto Whatman GF/C glass fibre filters under suction and is immediately washed with 5 ml icecold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non specific binding. Test value is calculated as the IC_{50} which is equivalent to the concentration which inhibits the specific binding by 50 percent.

Test results obtained by testing selected compounds of the present invention appear from the following table:

Table

Test compound:	IC_{50} (nM)
1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole	1.2
1-[3-(1-imidazolyl)-phenyl]-5-t-butyl-benzimidazole	2.4
1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole	7.4
1-[3-(1-imidazolyl)-phenyl]-5-i-propyl-benzimidazole	0.6
1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole	1.7
1-[3-(3-pyridyl)-phenyl]-5-t-butyl-benzimidazole	10
1-[3-(1-benzimidazolyl)-phenyl]-5-i-propyl-benzimidazole	4.3
1-[3-(1-(2-methylimidazolyl)-phenyl]-5-phenyl-benzimidazole	9
1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole	9.2
1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole	1.2
4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-ab][1,4]benzodiazepine	5.4

Pharmaceutical Compositions

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, then it is preferable to present the active ingredient as a pharmaceutical formulation.

The invention thus further provides a pharmaceutical formulation comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.

The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing one (1) milligram of active ingredient or, more broadly, 0.01 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.

The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the

active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from one to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated in solutions in aqueous polyethylene glycol solution.

The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray this may be achieved for example by means of a metering atomising spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon

(CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g. gelatin or blister packs from which the powder may be administered by means of an inhaler.

In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

When desired, formulations adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

Method of Treating

The compounds of this invention are extremely useful in the treatment of disorders or diseases of a living animal body due to their potent benzodiazepine receptor affinity. These properties make the compounds of this invention extremely useful in the treatment of convulsions, anxiety, sleep disorders, memory disorders as well as other disorders sensitive to benzodiazepine receptor binding activity. The compounds of this invention may accordingly be administered to a subject, including a human, in need of treatment, alleviation, or elimination of a disorder or disease associated with the benzodiazepine receptors. This includes especially convulsions, anxiety, sleep disorders and memory disorders.

Suitable dosage range are 0.01-100 milligrams daily, 0.1-50 milligrams daily, and especially 0.1-30 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

The following examples in the form of examples, methods and in the form of tables according to which compounds of the invention have been prepared will illustrate the invention further; however they are not to be construed as limiting.

EXAMPLE 1

1-(3-Iodophenyl)-5-trifluoromethylbenzimidazole (1a). A mixture of 2-amino-3'-iodo-4-trifluoromethyldiphenylamine (**1b**) (6.00 g, 14.4 mmol) and formic acid (60 ml) was refluxed for 16 h. After evaporation to dryness, the remanence was dissolved in ethyl acetate (100 ml) and washed with water (100 ml). The organic phase was dried and evaporated. The crude product was purified by column chromatography with methylene chloride as the eluent. Yield 4.2 g, mp 86-87°C.

EXAMPLE 2

1-(3-(1-Imidazolyl)-phenyl)-5 trifluoromethylbenzimidazole (3a). A mixture of **1a** (1.0 g, 2.58 mmol), imidazole (0.19 g, 2.73 mmol), potassium carbonate (0.38 g, 2.78 mmol), CuBr (20 mg, 0.15 mmol), and 1-methyl-2-pyrrolidone (5ml) was heated to 200°C for 18 hours. Dilution with water and extractive workup with ethyl acetate was followed by chromatography on silica gel. Yield: 0.43 g, mp. 177-180°C.

EXAMPLE 3

2-Amino-3'-iodo-4-trifluoromethyldiphenylamine hydrochloride (1b). A mixture of **1c** (6.0 g, 14.7 mmol), sodium sulfide nonahydrate (9.8 g, 44 mmol), ammonium chloride (2.35 g, 44 mmol), and 99% ethanol (100 ml) was refluxed under nitrogen for 3 hours. After cooling to room temperature the reaction mixture was poured into water (400ml) and extracted with ethyl acetate. The organic phase was washed with water, dried and con-

centrated. The remanence was purified by column chromatography. The product was converted to the hydrochloride by addition of methanolic hydrogen chloride to the eluate followed by evaporation of the solvent. Yield 6.0 g, mp. 182-185°C.

5 EXAMPLE 3a

Identical to Example 3 except for the products being isolated as the free bases.

10 EXAMPLE 4

2-amino-3'-(1-imidazolyl)-4-*i*-propyldiphenylamine hydrochloride (14b). A mixture of **14c** (1g, 3.11mmol) and palladium on activated carbon (5%, 0.1g) in MeOH (25ml) was hydrogenated at ambient pressure until the hydrogen uptake had ceased. The reaction mixture was filtered through celite into a few milliliters of ethereal hydrogen chloride. Evaporation of solvent left **14b** (0.95g, 2.89mmol). Mp. 185-190°C.

15

EXAMPLE 4a

Identical to Example 4 except for the products being isolated as the free bases.

20 EXAMPLE 5

3-Iodo-2-nitro-4-trifluoromethyldiphenylamine (1c). To a mixture of 3-iodoaniline (11.0g, 50mmol) and 4-chloro-3-nitrobenzotrifluoride (11.3g, 50mmol) in dry DMF (50ml) under nitrogen, was added sodium hydride (2.55g, 85mmol) in small portions over 0.5 hours. The reaction mixture was stirred at room temperature for 12 hours. The mixture was poured into water (200ml). Diethyl ether (300ml) was added and the phases were separated. The ethereal phase was washed with water (3x200ml), dried and evaporated. The crude product was purified by column chromatography using petroleum ether/methylenechloride (4:1) as the eluent. The crystalline product was triturated with petroleum ether and filtered. Yield 12.6g, mp. 98-101°C.

30 EXAMPLE 5a

As Example 5 but with dry potassium carbonate as the base and a reaction temperature of 120°C.

35 EXAMPLE 6

3'-Bromo-4-*t*-butyl-2-nitrodiphenylamine (6d). 4-*t*-Butyl-2-nitroaniline (see Example 7) (2g, 10.31mmol), 3-bromo-1-iodobenzene (5.84g, 20.62mmol), potassium carbonate (1.52g, 11mmol) and Cu-bronze (20mg) were thoroughly mixed and heated to 160°C overnight. After cooling the reaction mixture was partitioned between water and toluene. The organic phase was dried with MgSO₄ and evaporated. The remanence was passed through a silica gel column with ethyl acetate/petroleum ether (1:9) as the eluent to yield **6d** (2.27g, 61%). Mp 86-87°C.

40

EXAMPLE 7

4-*t*-Butyl-2-nitroaniline. 4-*t*-Butylaniline (5g, 33.58mmol) in acetic anhydride (25ml) was stirred at ambient temperature for 0.5h. The mixture was cooled in an ice-bath and nitric acid (6ml, 65%) was added at such a rate that the temperature did not exceed 18°C. Following the addition the mixture was poured on ice (200g). The precipitate was filtered off, washed thoroughly with water and dried to yield N-acetyl-4-*t*-butyl-2-nitroaniline (7.15g, 90%). Mp. 109-110°C.

50

This product (7g, 29.66mmol) was heated to reflux in sulfuric acid (30ml, 70%) for 0.5h. After cooling water (100ml) was added. The product was filtered off, washed with water and air-dried to yield 4-*t*-butyl-2-nitroaniline (5.4g, 94%). Mp. 107-108°C.

55 EXAMPLE 8

4-Acetaminobiphenyl. 4-Aminobiphenyl (15g, 88.76mmol) in toluene (250ml) was added acetic anhydride (8.5ml, 90mmol). The mixture was stirred at ambient temperature for 1 hour. Following the reaction the mixture was poured into petroleum ether (500ml), the product was filtered off, washed with petroleum ether and dried

to yield 4- acetaminobiphenyl (18.7g).

4-Acetamino-3-nitrobiphenyl. 4-Acetaminobiphenyl (17g, 80.57mmol) in glacial acetic acid (600ml) was added a solution of potassium nitrate (18g, 178mmol) in conc. sulphuric acid (75ml) at such a rate that the temperature was kept below 30°C. Following the addition the mixture was stirred at ambient temperature for 72 hours. The reaction mixture was poured into ice-water (1200ml). The product was filtered off, washed thoroughly with water and dried. Recrystallization from EtOH (99%, 150ml) afforded 4-acetamino-3-nitrobiphenyl (8.7g).

4-Amino-3-nitrobiphenyl. A mixture of N-acetyl-4-amino-3-nitrobiphenyl (8.5g, 33.2mmol), aqueous sodium hydroxide (100ml, 1M) and dimethoxyethane (75ml) was stirred at ambient temperature overnight. The mixture was poured into water (300ml). The product was filtered off, washed with water and dried to yield 4-amino-3-nitrobiphenyl (7g, 32.7mmol). Mp. 157-159°C.

EXAMPLE 9

2,6-Dinitro-4-trifluoromethyldiphenylamine (4k). 4-Chloro-3,5-dinitrobenzoetrifluoride (5g, 18.5mmol) in DMF (25ml) was added aniline (3.7ml, 40mmol) at 5°C. The mixture was allowed to warm to room temperature. After complete reaction the mixture was poured into water (100ml). The product was filtered off, washed with water and dried to yield the orange crystalline product. Yield 6.9g. Mp 118-120°C.

2-Amino-6-nitro-4-trifluoromethyldiphenylamine (4j). From 4k as described in Example 3. Mp 140-143°C.

7-Nitro-1-phenyl-5-trifluoromethylbenzimidazole (4i). From 4j as described in Example 1. Mp 95-98°C

7-Amino-1-phenyl-5-trifluoromethylbenzimidazole hydrochloride(4h). From 4i as described in Example 4.

7-Iodo-1-phenyl-5-trifluoromethylbenzimidazole (4g). To a cooled suspension of 4h (4.8g, 15mmol) in a mixture of water (12ml) and conc. hydrochloric acid (20ml) was added a solution of sodium nitrite (1.2g, 17mmol in 5ml water) at such a rate that the temperature was kept below 5°C. Following the addition the mixture was stirred for 10min. and a solution of potassium iodide (4g, 24mmol in 10ml water) was added carefully. The mixture was left at ambient temperature until the evolution of nitrogen had ceased (approx. 2h). Aqueous sodium sulphite was added and the product was filtered off. Purification was achieved by column chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:9) as the eluent. Yield 1.3g. Mp 118-120°C.

EXAMPLE 10

5-Amino-1-(3-(3-pyridyl)phenyl)benzimidazole (19a). 24a (1g, 3.16mmol) in conc. hydrochloric acid (10ml) was added tin(II)chloride (1.98g, 10.43mmol) and was refluxed overnight. After cooling the mixture was poured into water (50ml). Following filtration the filtrate was cooled in an ice-bath and rendered alkaline by addition of 12M sodium hydroxyde. A small volume of ethanol was added and the mixture was stirred at 0°C until a homogeneous suspension was obtained. The product was filtered off, washed with water and air-dried. Yield 0.9g. Mp 172-175°C.

EXAMPLE 11

1-(3-(3'-Amino)biphenyl)-5-*t*-butylbenzimidazole (20a). 43a (1g, 3.04mmol), sodium bicarbonate (1.28g, 15.2mmol), 3-aminophenylboronic acid and tetrakis(triphenylphosphine)palladium (30mg) was added to a mixture of water (10ml) and dimethoxyethane (20ml) under a stream of nitrogen. The reaction mixture was heated to 80°C overnight, cooled to room temperature and poured into water (100ml). A small volume of ethyl acetate was added and the mixture was stirred until the product had precipitated. Filtration and column chromatography on silica gel using ethyl acetate/petroleum ether (1:9) as the eluent yielded 20a (0.52g. Mp 162-164°C).

EXAMPLE 12

1-(3-Bromophenyl)-5-dimethylaminobenzimidazole hydrochloride (23a). 25a (0.8g, 2.78mmol) in DMF (10ml) was added potassium carbonate (0.83g, 6mmol) and iodomethane (0.36ml, 5.83mmol) and was stirred at ambient temperature for 4 hours. The mixture was poured into water (80ml) and extracted with ethyl acetate. The organic phase was dried over MgSO₄, concentrated to a small volume and eluted through silica gel with ethyl acetate/petroleum ether (1:9). The solvent was evaporated and the oily product was dissolved in dry diethyl ether and precipitated as the hydrochloride on addition of ethereal hydrochloric acid (2M). The product was filtered off and dried under nitrogen. Yield 0.21g. Mp 146-150°C.

EXAMPLE 13

5 5-*t*-Butyl-1-(5-(3-(2-pyridyl)oxadiazolyl))benzimidazole (26a). **44a** (0.75g, 2.55mmol) in THF (30ml) was heated to reflux. Carbonyldiimidazole (0.75g, 4.5mmol) was added and reflux was maintained for 1 hour. To 10ml of this solution pyridin-2-carbamidoxime (0.28, 2mmol) was added and the mixture was heated to reflux for 2 hours. After evaporation of the solvent, toluene (5ml) was added and the mixture was refluxed overnight. Removal of solvent left a crude product which precipitated upon trituration with water. The product was filtered off, dried and washed with petroleum ether. Yield 0.29g. Mp 139-141°C.

Compounds **27a-30a** and **33a** were prepared analogously from the appropriate carbamidoximes.

EXAMPLE 14

15 3-(4-Morpholinyl)nitrobenzene. 3-Nitroaniline (10g, 72mmol) in DMF (100ml) was added bis(2-chloroethyl) ether (11.7ml, 100mmol) and potassium carbonate (27.6g, 200mmol). The mixture was heated to reflux for 10 hours. Additional bis(2-chloroethyl) ether (3ml) was added and reflux was maintained for 18 hours. Addition of bis(2-chloroethyl) ether was repeated and reflux was continued for 4 hours. The solvent was evaporated and the residue partitioned between water and ethyl acetate. The organic phase was dried and evaporated. The residue was extracted with diethyl ether. The extract was concentrated and purified by column chromatography on silica gel with ethyl acetate/petroleum ether (3:7) as the eluent. Yield 3.4g. Mp 87-90°C.

20 3-(4-Morpholinyl)aniline. 3-(4-Morpholinyl)nitrobenzene (1.9g, 9.1mmol) was hydrogenated as described in Example 4. Yield 1.27g. Mp 115°C.

25 4-*t*-Butyl-3'-(4-morpholinyl)-2-nitrodiphenylamine (32c). 4-*t*-Butyl-1-iodo-2-nitrobenzene* (3g, 10mmol), 3-(4-morpholinyl)aniline (1.2g, 6.7mmol), potassium carbonate (1.38g, 10mmol) and Cu-bronze (30mg) was thoroughly mixed and heated to 170°C for 5 hours. The product was isolated and purified as described in Example 6. Yield 0.2g oily product.

* 4-*t*-Butyl-1-iodo-2-nitrobenzene was prepared from 4-*t*-butyl-2-nitroaniline (Example 7) in analogy with **4g** (Example 9).

EXAMPLE 15

30 *N,N'*-Bis(2-nitro-4-trifluoromethyl)-1,3-phenylenediamine (42c) and *N*-(2-nitro-4-trifluoromethyl)-1,3-phenylenediamine (45c). 4-Chloro-2-nitrobenzoetrifluoride (7.6ml, 50mmol) in dry DMF was added triethyl amine (7ml, 50mmol) and 1,3-phenylenediamine (3.24g, 30mmol). The mixture was heated to 80°C overnight and then to 120°C for 6 hours. The solvent was evaporated and the residue was partitioned between water and diethyl ether. The organic phase was dried and concentrated and the product mixture was separated by column chromatography on silica gel using diethyl ether/petroleum ether (1:1) as the eluent. Yield of **42c**: 3.7g, mp 133-135°C. Yield of **45c**: 3.7g, mp 110-112°C.

40 *N*-(2-Nitrophenyl)-*N'*-(2-nitro-4-trifluoromethylphenyl)-1,3-phenylenediamine (39c). **45c** (2g, 6.7mmol), 1-fluoro-2-nitrobenzene and potassium carbonate (1g, 7mmol) were thoroughly mixed and heated to 180°C for 3 days. After cooling the reaction mixture was partitioned between water and ethyl acetate. The organic phase was dried, concentrated and extracted with diethyl ether. The ethereal extract was passed through a short silica gel column to yield **39c**, 0.8g. Mp 95-98°C.

EXAMPLE 16

45 *N*-(Acetyl)-*N'*-(2-nitro-4-trifluoromethyl)-1,3-phenylenediamine (40c). **45c** (1.7g, 5.7mmol) and triethyl amine (0.84ml, 6mmol) in THF (20ml) was added acetylchloride (0.4ml, 6mmol). Following the addition water was added and the mixture was allowed to stir for 15min. The product was filtered off and air-dried. Mp 188-190°C.

EXAMPLE 17

50 4-*t*-Butyl-3'-carboxy-2-nitrodiphenylamine (44c). 4-*t*-Butyl-2-nitroaniline (see Example 7), 3-iodobenzoic acid (10g, 40mmol), potassium carbonate (5.5g, 40mmol) and a catalytic amount of CuI were thoroughly mixed and heated to 230°C for 4 hours. The reaction mixture was allowed to cool to 100°C and water was added. After cooling to room temperature the solution was rendered acidic by careful addition of glacial acetic acid. The precipitate was filtered off and washed with dichloromethane. Recrystallization from 2-propanol afforded **44c**. Yield 4.3g. Mp 194-195°C.

EXAMPLE 18

3-Acetyl-1,2-phenyldiamine hydrochloride was prepared from 3-acetyl-2-nitroaniline as described in Example 4. Mp 246-250°C.

4-Acetylbenzimidazole was prepared from 3-acetyl-1,2-phenyldiamine as described in Example 1. Mp 220-223°C.

4-Acetyl-1-(3-nitrophenyl)benzimidazole (3g). 4-Acetylbenzimidazole (4.4g, 27.5mmol) was dissolved in dry DMSO (40ml) and cooled. Sodium hydride (0.91g, 80% suspension in oil) was added and the mixture was allowed to warm to room temperature. When the evolution of hydrogen had ceased 1-fluoro-3-nitrobenzene was added and the mixture was heated to 120°C overnight. After cooling the reaction mixture was poured into ice-water and the crude product was filtered off. Purification was achieved by column chromatography on silica gel with ethyl acetate/petroleum ether (1:1) as the eluent. Yield 2.09g, mp 175-177°C.

EXAMPLE 19

4-Nitrobenzimidazole was prepared from 3-nitro-1,2-phenyldiamine as described in Example 1. Mp 242-245°C.

4-Nitro-1-(3-nitrophenyl)benzimidazole was prepared analogously to **3g** from 4-nitrobenzimidazole and 1-fluoro-3-nitrobenzene. Mp 260-262°C.

1-(3-Aminophenyl)-4-nitrobenzimidazole was prepared from 4-nitro-1-(3-nitrophenyl)benzimidazole as described in Example 3a. Mp 159-161°C.

4-Nitro-1-(3-pivaloylamino-phenyl)benzimidazole (5g). 1-(3-Aminophenyl)-4-nitrobenzimidazole (0.15g, 0.6mmol) was suspended in THF (4ml). Triethyl amine (0.084ml, 0.6mmol) and pivaloylchloride (0.074ml, 0.6ml in 1ml THF) was added. After stirring for 3 hours at room temperature another equivalent of pivaloylchloride was added and the temperature was raised to 70°C for 0.5 hours. After evaporation of solvent the residue was extracted with ethyl acetate. The extract was dried over MgSO₄ and the solvent was removed by evaporation. Trituration with petroleum ether containing a few percent dichloromethane afforded **5g**. Yield 0.12g, mp 105-110°C.

EXAMPLE 20

4-*t*-Butyl-1-fluorobenzene. 4-*t*-Butylaniline (14.9g, 100mmol) was suspended in aqueous hydrochloric acid (50ml, 6M) at 5°C. Sodium nitrite (7.6g, 110mmol in 10ml water) was added at such a rate that the temperature was kept between 5-7°C. Following the addition the resulting solution was stirred for 15 min. and sodium tetrafluoroborate (15.4g, 140mmol in 30ml water) was added at 5-8°C. The mixture was stirred for 15 min. 4-*t*-Butylbenzenediazonium tetrafluoroborate was filtered off, dried with suction and washed with diethyl ether to yield 20.96g. This diazonium salt was decomposed by heating to 140°C on an oil-bath. The product was distilled off at reduced pressure. Yield 11.15g colorless oil.

4-*t*-Butyl-1-fluoro-2-nitrobenzene. 1-Fluoro-4-*t*-butylbenzene (10g, 65.79mmol) was dissolved in concentrated sulfuric acid (40ml) at 0°C. Solid potassium nitrate (6.64g, 65.79mmol) was added in small portions during 1 hour. The temperature was kept below 5°C. Following the addition stirring was continued for 2 hours. The reaction mixture was poured into ice-water (400ml) and extracted with dichloromethane (3x50ml). The organic phase was washed with water, aqueous sodium bicarbonate (1M) and water successively, dried over MgSO₄ and filtered through silica gel (5g). Evaporation of solvent left the crude product (10.32g). Column chromatography on silica gel using petroleum ether containing 1% dichloromethane as the eluent afforded the pure product (7.6g colorless oil).

N-(2-Bromo-6-pyridyl)-4-*t*-butyl-2-nitroaniline. 4-*t*-Butyl-1-fluoro-2-nitrobenzene (1.97g, 10mmol), 2-amino-6-bromopyridine (1.73g, 10mmol) and potassium carbonate (1.38g, 10mmol) were thoroughly mixed and heated to 150°C overnight. The temperature was raised to 180°C for 30 hours. After cooling water and a small amount of ethyl acetate was added and the mixture was stirred for 1 hour. The organic phase was dried and concentrated and eluted through silica gel with petroleum ether/diethyl ether (9:1). Yield: 1.25g, mp 78-81°C.

2-Amino-*N*-(2-bromo-6-pyridyl)-4-*t*-butylaniline was prepared from *N*-(2-bromo-6-pyridyl)-4-*t*-butyl-2-nitroaniline (1.25g, 3.57mmol) as described in Example 3. Yield: 0.85g, mp 125-128°C.

1-(2-Bromo-6-pyridyl)-5-*t*-butylbenzimidazole (6g) was prepared from 2-Amino-*N*-(2-bromo-5-pyridyl)-4-

t-butylaniline (0.8g) as described in Example 1. Yield: 10mg* , mp 98-100°C.


EXAMPLE 21

5 1-(3-Bromophenyl)-4-nitrobenzimidazole (7g). 4-Nitrobenzimidazole (see Example 19. 0.75g, 4.6mmol), 1,3-dibromobenzene (1.11ml, 9.2mmol), potassium carbonate (0.64g, 4.6mmol) and a catalytic amount of Cu-bronze were mixed in dry 1-methyl-2-pyrrolidone (2ml) and heated to 140°C for 3 days. One equivalent of 1,3-dibromobenzene was added and heating was continued for 24 hours. The cooled reaction mixture was extracted with ethyl acetate. The extract was dried and concentrated and eluted through silica gel with ethyl acetate/methanol (9:1) to yield 7g (33mg, mp 180-182°C).

EXAMPLE 22


15 Ethyl N-(2,6-dinitro-4-trifluoromethylphenyl)anthranilate (1i). To a mixture of 4-chloro-3,5-dinitrobenzoetrifluoride (6.76g, 25mmol) and ethyl anthranilate (3.7ml, 25mmol) in dry DMF (20ml) was added sodium hydride (30mmol, 1.2g 60% suspension in oil) in small portions. The mixture was stirred at 80°C overnight, cooled and poured into ice-water (400ml). The product was filtered off, washed with water and dried. Recrystallization from ethanol (200ml) yielded 1i (7.27g, mp 152-154°C).

20 1j. 1i (3.42g, 8.56mmol) and ammonium chloride (1.37g, 25.7mmol) in ethanol (50ml) was added a solution of sodium sulfide nonahydrate (6.17g, 25.7mmol in 50ml ethanol) at 0°C. The mixture was allowed to heat to room temperature. After 1 hour the mixture was filtered and the filtrate was evaporated to dryness. Trituration of the residue with ethyl acetate/ petroleum ether (1:9) and diethyl ether successively afforded 1j. Yield: 2.28g, mp 285-293°C.



1j

40 1h. 1j (1.43g, 4.42mmol) was hydrogenated as described in Example 4. The product was isolated as the free base. Yield: 0.66g.



1h

50 1f (see Table 5 for structure) was prepared from 1h (0.66g, 2.24mmol) as described in Example 1. Yield: 0.42g, mp 330-332°C.

* Most of the starting material was formylated without ring-closure.

EXAMPLE 23

2f (see Table 5 for structure) 1f (1g, 3.3mmol) in dry DMF (10ml) was added sodium hydride (0.1g, 3.3mmol) at 0°C. Following the addition the mixture was stirred at ambient temperature for 20min. Iodomethane (0.52g, 3.66mmol) was added and stirring was continued for 4 hours. The reaction mixture was poured into water (40ml), the product was filtered off and dried. Trituration with dry diethyl ether yielded 2f (0.37g, mp 197-198°C).

EXAMPLE 24


4f (see Table 5 for structure). 2f (0.1g, 0.33mmol) in dry THF (4ml) was added LiAlH₄ (10mg, 0.33mmol) at 0°C. The reaction mixture was stirred for 15min. and poured into ice-water (10ml). The product was filtered off and dried to yield 4f (0.1g, mp 169-170°C).

EXAMPLE 25

2',6'-Dinitro-2-hydroxymethyl-4'-trifluoromethyldiphenylamine (5j). A mixture of 4-chloro-3,5-dinitrobenzoetrifluoride (10g, 36.96mmol), 2-hydroxymethylaniline (5g, 40.66mmol) and potassium carbonate (5.1g, 36.96mmol) in DMF (250ml) was stirred at ambient temperature for 1.5 hours. The reaction mixture was poured into ice-water (1l) and the product was filtered off. Trituration with petroleum ether containing a small amount of dichloromethane afforded 5j (9.73g, mp 117-120°C).

2',6'-Dinitro-2-(4-toluenesulfonyloxymethyl)-4'-trifluoromethyldiphenylamine (5l). 5j (9g, 25.19mmol) in pyridine (55ml) was added 4-toluenesulfonyl chloride in small portions at ambient temperature. Following the addition the mixture was stirred at 40°C overnight, poured into ice-water and acidified with hydrochloric acid. The product was extracted with ethyl acetate and isolated by evaporation of the solvent. Trituration with diethyl ether afforded pure 5l. Yield 13.49g.

5h. 5l (7g, 13.69mmol) and ammonium chloride (4.4g, 82.12mmol) in ethanol (250ml) was added sodium sulfide (19.7g, 82.12mmol) in small portions at 0°C. Following the addition the mixture was stirred at ambient temperature for 5 hours. Filtration and evaporation of solvent left a crude product, which upon extraction with diethyl ether and column chromatography on silica gel using ethyl acetate/petroleum ether (1:1) as the eluent afforded pure 5h (1.51g, mp 135-138°C):

**5 h**

5f (see Table 5 for structure). 5h (1.46g, 5.23mmol) was refluxed in formic acid (50ml) for 1.5 hours. The cooled mixture was poured into water (200ml) and extracted with ethyl acetate. The extract was eluted through silica gel with ethyl acetate to yield a formylated product which upon reflux in ethanolic sodium hydroxide afforded 5f. Yield 0.58g, mp 242-243°C.

EXAMPLE 26

N-(4-Methyl-2-nitrophenyl)anthranilic acid (6j). 2-Iodobenzoic acid (5g, 20.16mmol), 4-methyl-2-nitroaniline (6.12g, 40.32mmol), potassium carbonate (2.8g, 20.3mmol) and CuI (0.2g) were thoroughly mixed and heated to 200°C for 1 hour. After cooling the solid reaction mixture was partitioned between ethyl acetate and aqueous sodium hydroxide (1M). The product precipitated from the aqueous phase on acidification with hydrochloric acid (4M). Yield 3.69g, mp 209-213°C.

9,10-Dihydro-2-methyl-4-nitroacredin-9-one (6i). 6j (2.56g, 9.41mmol) was heated to 100°C in conc. sulfuric acid (6ml) for 1 hour. After cooling the mixture was poured into ice-water (50ml). The product was filtered

off, washed with water and air-dried. Quantitative yield, mp 232-234°C.

9,10-Dihydro-4-amino-2-methylacredin-9-one (**6h**) was prepared from **6i** (2g, 7.87mmol) as described in Example 3. Yield 1.4g, mp 292-297°C.


6f (see Table 5 for structure) was prepared from **6h** (1g, 4.46mmol) as described in Example 1. Yield after recrystallization from ethanol: 0.4g, mp 255-257°C.

EXAMPLE 27

Imidazo[6,7-d]phthalide (**3h**) was prepared from 6,7-diaminophthalide (3.7g, 22.57mmol) as described in Example 1. Yield 3.8g, mp 280°C.

6-(3-nitrophenyl)imidazo[6,7-d]phthalide (**3e**). **3h** (0.45g, 2.5mmol) in dry DMSO was added sodium hydride (0.1g 80% suspension in oil). After the evolution of nitrogen had ceased 3-fluoronitrobenzene (0.32ml, 3mmol) was added and the mixture was stirred at 120°C for 2 days. After cooling water and a few drops of glacial acetic acid was added. The product was filtered off and purified by column chromatography on silica gel using dichloromethane/aceton (9:1) as the eluent. Yield 9mg, Mp 266-268°C.


EXAMPLE 28



5-bromo-6,8-dihydro-7-methyl-2H-pyrrolo[3,4-e]benzimidazole.

A solution of 7-bromo-2,3-dihydro-2-methyl-1H-isoindole (0.6g) in formic acid (10 ml) was refluxed for 5 hours, whereafter it was evaporated to dryness. The residue was treated with a mixture of water/EtOAc (5/5 ml). pH was adjusted to 9 with sodium carbonate, whereby the title compound precipitated as pale crystals. Mp. 225-227°C.

EXAMPLE 29



The above product was hydrogenated under standard conditions to give 2,3-dihydro-2-methyl-1H-isoindole hydrobromide with Pd/C as the catalyst. Mp. > 300°C.

EXAMPLE 30



3-(3-bromophenyl)-6,8-dihydro-7-methyl-2H-pyrrolo[3,4-e]benzimidazole.

A mixture of 6,8-dihydro-7-methyl-2H-pyrrolo[3,4-e]benzimidazole (0.25g), K₂CO₃ (0.26g), 3-bromo-1-iodobenzene (0.8g) and Copper powder (15-20mg) was heated in N-methyl-2-pyrrolidone (5ml) at 180°C for 3

hours. The mixture was then partitioned between EtOAc and water. The organic phase was dried over Na_2SO_4 and evaporated. The oily residue was purified on SiO_2 with EtOAc as the eluent. $^1\text{H-NMR}$ (500MHz, CDCl_3) ppm: 2.8(s,3H), 4.2(s,2H), 4.45(s,2H), 7.2-7.7(m,6H aromatic) 8.1(s,1H imidazole).

5 EXAMPLE 31

3-(3-Nitrophenyl)-benzo[e]benzimidazole (2k). To **3k** (2.2g, 13mmol) in dry DMSO (30ml) was added sodium hydride (0.43g 80% in oil, 14.3mmol) at 0°C . When evolution of hydrogen had ceased 3-fluoronitrobenzene (1.52ml, 14.3mmol) was added and the mixture was heated to $110-120^\circ\text{C}$ for 2 days. After cooling the mixture was diluted with 4 volumes of water and extracted with ethyl acetate. Drying and evaporation of solvent followed by trituration with ethanol left **2k** as yellow crystals (1.49g, 40%). Mp $136-138^\circ\text{C}$.

3-(3-Nitrophenyl)-pyrido[1,3-e]benzimidazole (4k) was prepared analogously from **5k** (0.7g, 4.14mmol). Yield 0.25g (21%). Mp $219-221^\circ\text{C}$.

3-(3-nitrophenyl)-7-methyl-piperido[3,4-e]benzimidazole hydrochloride (6k) was prepared analogously from **7k** (1.56g, 7mmol) using two equivalents of sodium hydride. Yield 70mg (3%). Mp $266-269^\circ\text{C}$.

EXAMPLE 32

1,2-Diaminonaphthalene hydrochloride was prepared analogously to 2-methyl-1,2,3,4-tetrahydroisoquinoline as described in United States patent application Ser. No. 08/124,770 of September 24, 1993. Mp $223-226^\circ\text{C}$.

5,6-Diaminoquinoline hydrochloride was prepared from 5-amino-6-nitroquinoline (1g, 5.29mmol) as described in Example 4. Yield 1.0g (97%). Mp $214-220^\circ\text{C}$.

25 EXAMPLE 33

1-(3-(3-pyridyl)phenyl)-5-hydroxymethylbenzimidazole (49a). **48a** (3.5g, 9.8mmol) in dry THF (25ml) was added LiAlH_4 (0.36g, 4.9mmol) portionswise during 1 hour at 0°C under N_2 . Following the addition the mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried with MgSO_4 and evaporated. The residue was eluted through silica gel with EtOH/MeOH mixture (9:1). Evaporation of solvent from the pure fractions left **49a**. Yield 1.58g (54%). Mp $183-185^\circ\text{C}$.

EXAMPLE 34

1-(3-(3-pyridyl)phenyl)-5-formylbenzimidazole (50a). **49a** (0.68g, 2.26mmol) in toluene (5ml) was added benzeneseleninic acid (0.64g, 3.39mmol). The mixture was heated to 70°C for 5 hours. After cooling the product was filtered off and washed with warm toluene and CH_2Cl_2 successively. Yield 0.58g (86%). Mp $200-202^\circ\text{C}$.

40 EXAMPLE 35

1-(3-(3-pyridyl)phenyl)-5-aldoximobenzimidazole (52a). **50a** (0.25g, 0.84mmol) in abs. EtOH (10ml) was added hydroxylamine hydrochloride (0.17g, 2.48mmol). The suspension was heated to 70°C for 30 min. After cooling water was added. The product was filtered off, washed with water and air-dried to yield **52a** (0.14g, 53%). Mp $228-230^\circ\text{C}$.

EXAMPLE 36

1-(3-(3-pyridyl)phenyl)-5-semicarbazobenzimidazole (55a). Analogously to **52a** with addition of one equivalent pyridine to the reaction mixture. Yield 0.18g (60%). Mp $275-278^\circ\text{C}$.

EXAMPLE 37

1-Phenyl-5-trifluoromethyl-7-benzoylaminobenzimidazole (15g). **14g** (0.3g, 1.08mmol) in THF (10ml) was added triethylamine (0.3ml) and benzoylchloride (0.23ml). The mixture was stirred at ambient temperature overnight. The solvent was removed *in vacuo* and the remanence was partitioned between water and ethyl acetate. The organic phase was dried and evaporated. The oily residue was dissolved in diethyl ether, and the product precipitated upon addition of petroleum ether. Yield 0.15g (36%). Mp $152-155^\circ\text{C}$.

EXAMPLE 38

1-(3-Bromophenyl)-5-methoxymethylbenzimidazole (**66a**). **65a** (1g, 3.3mmol) in dry DMF (10ml) was added sodium hydride (0.11g 80% in oil, 3.63mmol) at 0°C. When evolution of hydrogen had ceased iodomethane (0.23ml, 3.63mmol) was added, and the mixture was stirred at 40°C for 1 hour. Dilution with water and extractive workup with ethyl acetate followed by column chromatography on silica gel, using ethyl acetate as the eluent, afforded **66a** as a colorless oil. Yield 0.52g (59%).

10

15

20

25

30

35


40

45

50

55

Table 1. Compounds 1a-66a.



No.	R ₁	R ₂	Mp/°C	Starting material	Example
1a	CF ₃	I	86-87	1b	1
2a	Me	CN	142-143	2b	1
3a	CF ₃	1-imidazolyl	177-180	1a	2
4a	<i>i</i> -PrO ₂ C	1-imidazolyl	125-128	4b	1
5a	Me	1-imidazolyl	167-168	5b	1
6a*	<i>t</i> -Bu	1-imidazolyl	200-210	6b	1
7a	<i>t</i> -Bu	1-(4-phenylimidazolyl)	175-177	7b	1
8a*	<i>t</i> -Bu	1-(4-methylimidazolyl)	215-225	8b	1
9a	Ph	1-imidazolyl	163-164	9b	1
10a	<i>n</i> -Bu	1-imidazolyl		10b	1
11a	<i>n</i> -Bu	1-(4-phenylimidazolyl)		11b	1
12a	<i>n</i> -Bu	1-(2-methylimidazolyl)		12b	1
13a*	(CH ₂) ₅ CH	1-imidazolyl	222-225	13b	1
14a*	<i>i</i> Pr	1-imidazolyl	208-212	14b	1
15a	<i>i</i> Pr	1-(4-phenylimidazolyl)	215-218	15b	1
16a	<i>i</i> Pr	1-(2-methylimidazolyl)		16b	1
17a	NO ₂	1-benzimidazolyl	237-240	31a	2
18a	I	3-pyridyl	200-202	19a	9
19a	NH ₂	3-pyridyl	172-175	24a	10
20a	<i>t</i> -Bu	3-aminophenyl	162-164	43a	11
21a	<i>t</i> -Bu	3-furanyl	118-120	43a	11 ^b
22a	<i>t</i> -Bu	3-pyridyl	137-140	43a	11 ^c
23a*	NMe ₂	Br	146-150	25a	12
24a	NO ₂	3-pyridyl	229-230	31a	11 ^c
25a	NH ₂	Br	140-142	31a	10
26a	<i>t</i> -Bu	5-(3-(2-pyridyl)oxadiazolyl)	139-141	44a	13
27a	<i>t</i> -Bu	5-(3-(3-pyridyl)oxadiazolyl)	138-143	44a	13

	28a	<i>t</i> -Bu	5-(3-(4-pyridyl)oxadiazolyl)	94-96	44a	13
	29a	<i>t</i> -Bu	5-(3-(2-furanyl)oxadiazolyl)	157-159	44a	13
5	30a	<i>t</i> -Bu	5-(3-cyclopropyl)oxadiazolyl	176-178	44a	13
	31a	NO ₂	Br	187-189	31b	1
	32a	<i>t</i> -Bu	4-morpholinyl	141-143	32b	1
10	33a	<i>t</i> -Bu	5-(3-methyl)oxadiazolyl	142-145	44a	13
	34a	<i>i</i> -Pr	1-benzimidazolyl	150-152	34b	1
	35a	<i>t</i> -Bu	1-(5- <i>t</i> -butyl)benzimidazolyl	263-265	35b	1
	36a	NO ₂	1-imidazolyl	232-234	31a	2
15	37a	<i>t</i> -Bu	CN	138-140	37b	1
	38a	Ph	1-(2-methyl)imidazolyl	192-194	9b	1
	39a	CF ₃	1-benzimidazolyl	275-279	39b	1
	40a*	CF ₃	3-acetamino	223-226	40b	1
20	41a	HCONH	1-imidazolyl	234-235	41b	1 ^d
	42a	CF ₃	1-(5-trifluoromethyl)- benzimidazolyl	171-172	42b	1
25	43a	<i>t</i> -Bu	Br	132-134	43b	1
	44a	<i>t</i> -Bu	COOH	215-216	44b	1
	45a	3-furanyl	3-pyridyl	160-163	18a	11 ^b
	46a	Ph	3-pyridyl	139-141	18a	11 ^e
30	47a	<i>i</i> -PrO ₂ C	Br	102-104	47b	1
	48a	<i>i</i> -PrO ₂ C	3-pyridyl	108-111	47a	11 ^c
	49a	CH ₂ OH	3-pyridyl	183-185	48a	33
35	50a	CHO	3-pyridyl	200-202	49a	34
	51a	3-pyridyl	3-pyridyl	178-182	18a	11 ^c
	52a	CHNOH	3-pyridyl	228-230	50a	35
40	53a	3-(3-cyclo- propyl)oxa- diazolyl	3-pyridyl	178-180	48a	13
	54a	2-nitrophenyl	3-pyridyl	195-197	18a	11 ^f
45	55a	CHNNH ₂ - C(O)NH ₂	3-pyridyl	275-278	50a	36
	56a	1-imidazolyl	3-pyridyl	187-190	18a	2
	57a	2-furanyl	3-pyridyl	160-165	18a	29
50	58a	CH ₂ OCH ₃	3-pyridyl	119-120	66a	11 ^c
	59a	CHNOCH ₃	3-pyridyl	205-207	50a	35 ^h
	60a*	<i>i</i> -Pr	3-pyridyl	155-160	61a	11 ^c
55	61a	<i>i</i> -Pr	Br	82-86	61b	1

	62a*	cyclopropyl- Br methyloxy	160-168	63a	38 ⁱ
5	63a	OH Br	230-234	63b	1j
	64a	benzyloxy Br	189-193	63a	33 ^k
	65a	CH ₂ OH Br	112-114	47a	33
	66a	CH ₂ OCH ₃ Br	**	65a	38

10

* isolated as the hydrochloride

**isolated as an oil

a decomp.

15

b Starting from 3-furanylboronic acid

c Starting from diethyl 3-pyridylborane

d The 5-amino group is formylated during the reaction

20

e Starting from phenylboronic acid

f Starting from 2-nitrophenylboronic acid

g Starting from 2-(tributylstannyl)furane

h Starting from methoxylamine hydrochloride

25

30

35

40

45


50

55

Table 2. Compounds 1b-63b.

5

10



15

No	R ₁	R ₂	Mp/°C	Starting material	Example
1b*	CF ₃	I	182-185	1c	3
2b	Me	CN	173-174	2c	3a
4b	<i>i</i> -PrO ₂ C	1-imidazolyl	**	4c	4a
5b	Me	1-imidazolyl	143-148	5c	3a
6b	<i>t</i> -Bu	1-imidazolyl	184-187	6c	3a
7b	<i>t</i> -Bu	1-(4-phenylimidazolyl)	**	7c	4a
8b	<i>t</i> -Bu	1-(4-methylimidazolyl)	**	8c	4a
9b	Ph	1-imidazolyl	210-215	9c	3a
10b	<i>n</i> -Bu	1-imidazolyl		10c	4
11b	<i>n</i> -Bu	1-(4-phenylimidazolyl)		11c	4
12b	<i>n</i> -Bu	1-(2-methylimidazolyl)		12c	4
13b*	(CH ₂) ₅ CH	1-imidazolyl	175-181	13c	4
14b*	<i>i</i> -Pr	1-imidazolyl	185-190	14c	4
15b*	<i>i</i> -Pr	1-(4-phenylimidazolyl)	265-268	15c	4
16b	<i>i</i> -Pr	1-(2-methylimidazolyl)		16c	4
31b	NO ₂	Br	177-179	31d	3a
32b	<i>t</i> -Bu	4-morpholinyl	**	32c	3a
34b	<i>i</i> -Pr	1-benzimidazolyl	**	34c	4a
35b	<i>t</i> -Bu	(2-amino-4- <i>t</i> -butyl-phenyl)amino	222-224	35c	4a
37b*	<i>t</i> -Bu	CN	207-208	37c	4
39b	CF ₃	(2-aminophenyl)amino	**	39c	4a
40b*	CF ₃	acetamino	219-221	40c	4
41b*	NH ₂	1-imidazolyl	258-262	41c	4
42b*	CF ₃	(2-amino-4- <i>t</i> -butylphenyl)-amino	170-173	42c	4
43b*	<i>t</i> -Bu	Br	213-215	43c	3
44b	<i>t</i> -Bu	COOH	158-160	44c	4a

55

	47b	i-PrO ₂ C	Br	98-101	47d	3a
	61b*	i-Pr	Br	197-203	14d	3
5	63b	cyclopro- pymethoxy	Br	122-125	63c	3a

10 *isolated as the hydrochloride.
 **isolated as an oil.

15

20

25

30

35


40

45

50

55

Table 3. Compounds 1c-63c.



No.	R ₁	R ₂	Mp/°C	Starting material	Example
1c	CF ₃	I	98-101		5a
2c	Me	CN	162-163		2b
4c	<i>i</i> -PrO ₂ C	1-imidazolyl	**	4d	2
5c	Me	1-imidazolyl	124-126	5d	2
6c	<i>t</i> -Bu	1-imidazolyl	**	6d	2
7c	<i>t</i> -Bu	1-(4-phenylimidazolyl)	**	6d	2
8c	<i>t</i> -Bu	1-(4-methylimidazolyl)	**	6d	2
9c	Ph	1-imidazolyl	114-120	9d	2
10c	<i>n</i> -Bu	1-imidazolyl		10d	2
11c	<i>n</i> -Bu	1-(4-phenylimidazolyl)		10d	2
12c	<i>n</i> -Bu	1-(2-methylimidazolyl)		10d	2
13c	(CH ₂) ₅ CH	1-imidazolyl	**	13d	2
14c	<i>i</i> -Pr	1-imidazolyl	65-66	14d	2
15c	<i>i</i> -Pr	1-(4-phenylimidazolyl)	123-124	14d	2
16c	<i>i</i> -Pr	1-(2-methylimidazolyl)		14d	2
32c	<i>t</i> -Bu	4-morpholinyl	**		14
34c	<i>i</i> -Pr	1-benzimidazolyl	**	14d	2
35c	<i>t</i> -Bu	(2-nitro-4- <i>t</i> -butylphenyl)-amino	120-122		6c
37c	<i>t</i> -Bu	CN	83-84		6b
39c	CF ₃	(2-nitrophenyl)amino	95-98	45c	15
40c	CF ₃	acetamino	188-190	45c	16
41c	NO ₂	1-imidazolyl	167-169	31d	2
42c	CF ₃	(2-nitro-4-trifluoromethyl-phenyl)amino	133-135		15
43c	<i>t</i> -Bu	Br	74-76	6d	6

44c	<i>t</i> -Bu	COOH	194-195	17
45c	CF ₃	NH ₂	110-112	15
63c	cyclopro- pymeth- oxy	Br	76-82	64/38 ^a

****isolated as an oil.**

^a commercial available starting materials are not listed.


^b starting from 4-methyl-2-nitroaniline and 3-bromobenzonitrile.

^c 2 equivalents of 4-*t*-butyl-2-nitroaniline was used.

^d using 1,3-dibromobenzene.

^e using bromomethylcyclopropane.

Table 4. Compounds 4d-47d.



No.	R	X	Mp/°C	Example
4d	<i>i</i> -PrO ₂ C	I	176-179	5a ^a
5d	Me	Br	103-104	6
6d	<i>t</i> -Bu	Br	86-87	6/7
9d	Ph	Br	109-110	6/8
10d	<i>n</i> -Bu	Br	**	6/7
13d	(CH ₂) ₅ CH	Br	**	6/7
14d	<i>i</i> -Pr	Br	51-52	6/7 ^b
31d	NO ₂	Br	170-172	5a ^c
47d	<i>i</i> -PrO ₂ C	Br	162-165	5a ^d


****isolated as an oil.**

^a starting from isopropyl 4-chloro-3-nitrobenzoate and 3-iodoaniline.

^b a catalytic amount of conc. sulfuric acid was added to the acetanilide/acetic anhydride suspension prior to nitration.

^c starting from 2,4-dinitrofluorobenzene and 3-bromoaniline.

^d starting from 2,4-dinitrofluorobenzene and 3-bromoaniline.


Table 5. Compounds 1f-8f.

No.	A	B	R	Mp/°C	Starting material	Example
1f	NH	C=O	CF ₃	330-332		22
2f	NMe	C=O	CF ₃	197-198	1f	23
3f	NEt	C=O	CF ₃	173-174	1f	23 ^a
4f	NMe	CHOH	CF ₃	169-170	2f	24
5f	N	CH	CF ₃	242-243		25
6f	not present	C=O	Me	255-257		26
7f	not present	C=O	<i>t</i> -Bu	240-242		26 ^b
8f	not present	CHOH	<i>t</i> -Bu	188-190	7f	24

^a Using iodoethane instead of iodomethane.

^b Starting from 4-*t*-butyl-2-nitroaniline. Example 7.

Table 6. Compounds 1g-15g.



No.	R ₁	R ₂	R ₃	R ₄	X	Mp/°C	Starting material	Ex.
1g	H	CF ₃	3-pyridyl	H	CH	118-120	4g	11 ^a
2g	H	CF ₃	3-aminophenyl	H	CH	202-205	4g	11
3g	COCH ₃	H	H	NO ₂	CH	175-177		18
4g	H	CF ₃	I	H	CH	118-120		9
5g	NO ₂	H	H	3-pivaloylamino	CH	105-110		19
6g	H	<i>t</i> -Bu	H	Br	N	98-100		20
7g	NO ₂	H	H	Br	CH	180-182		21
8g	H	CF ₃	NH ₂	Ph	CH	70-71	9g	4
9g	H	CF ₃	NO ₂	Ph	CH	150-152		9 ^b
10g	H	CF ₃	3-aminophenyl	CN	CH	211-215	11g	11
11g	H	CF ₃	I	CN	CH	174-175		9 ^c
12g	H	CF ₃	Ph	H	CH	174-176	13g	11 ^d
13g	H	CF ₃	I	H	CH	118-120	14g	9 ^e
14g [*]	H	CF ₃	NH ₂	H	CH	~		9 ^f
15g	H	CF ₃	PhCONH	H	CH	152-155	14g	37

* Isolated as the hydrochloride.

**Used without purification.

^a Using diethyl 3-pyridylborane


^b Analogously to 4i from 4-chloro-3,5-dinitrobenzoetrifluoride and 3-aminobiphenyl.

^c Analogously to 4g from 4-chloro-3,5-dinitrobenzoetrifluoride and 3-aminobenzonitril.

^d Using phenylboronic acid.

^e Analogously to 4g.

^f Analogously to 4h starting from 4-chloro-3,5-dinitrobenzoetrifluoride.

Table 7. Compounds 1k-11k.

No.	R ₁	R ₂	R ₃	Mp/°C	Starting material	Example
1k	=N-S-N=		3-iodophenyl	193-195	1I	1/3
2k	-CH=CH-CH=CH-		3-nitrophenyl	136-138	3k	3I
3k	-CH=CH-CH=CH-		H	273-285	1,2-diamino-naphthalene	1/32
4k	-CH=CH-CH=N-		3-nitrophenyl	219-221	5k	3I
5k	-CH=CH-CH=N-		H	270-272	5,6-diamino-quinoline	1
6k	-CH ₂ -N(CH ₃)-(CH ₂) ₂ -		3-nitrophenyl	266-269	7k	3I
7k	-CH ₂ -N(CH ₃)-(CH ₂) ₂ -		H	297-299	5,6-diamino-3-methyl-1,2,3,4-tetrahydroisoquinoline	32
8k	H	<i>t</i> -Bu	8-isoquinolyl	253-260	8I	1/3
9k	H	CF ₃	5-quinolyl	181-183	9I	1/4
10k	H	CF ₃	6-quinolyl	190-194	10I	1/4
11k	H	CF ₃	1-naphtyl	170-173	11I	1/3


* Isolated as the hydrochloride.

**Preparation as described in United States patent appln. Ser. No. 08/124,770 of Sept. 24, 1993

Table 8. Compounds 1I-11I.

5

10



15

20

25

No.	R ₁	R ₂	R ₃	Mp/°C	Starting material	Example
1I	=N-S-N=		3-iodophenyl	224-225	4-chloro-3-nitrobenzothiadiazole	5a
8I	H	CF ₃	8-isoquinolyl	*	8-bromoisoquinoline	6
9I	H	CF ₃	5-quinolyl	138-140	5-aminoquinoline	5a
10I	H	CF ₃	6-quinolyl	158-160	6-aminoquinoline	5a
11I	H	CF ₃	1-naphtyl	148-150	1-aminonaphtalene	5a

* Isolated as an oil.


30

Claims

35

1. A compound having the formula:

40




45

or a pharmaceutically acceptable salt thereof


wherein

R³ is


50



55



or



wherein

X is N; or C-R' wherein R' is hydrogen or together with R⁴ forms a -(NR¹¹¹)_m-C(=O)-, -(NR¹¹¹)_m-

CHOH-, or a -N=C- bridge wherein R¹¹ is hydrogen or alkyl and m is 0 or 1;

one of A, B, C, and D is N and the others are CH;


one of E, F, G, and K is N-R" wherein R" is hydrogen or alkyl and the others of E, F, G, and K are CH₂;

R⁶ and R⁷ are independently hydrogen; halogen; amino; nitro; cyano; acylamino; trifluoromethyl; alkyl; alkoxy; COO-alkyl; acyl; CH=NOH, CH=NO-alkyl; CH=N-NH-(C=O)-NH₂; phenyl which may be substituted one or more times with alkyl, nitro, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁶ and R⁷ together forms a (CH₂)_a-(Z)_b-(C=Y)_c-(Z')_d-(CH₂)_e bridge wherein each of Z and Z' independently are O, S, or NR¹¹ wherein R¹¹ is hydrogen or alkyl, Y is O or H₂, a and e are each independently 0, 1, 2, or 3 and b, c, and d are each independently 0 or 1 provided that the sum of a, b, c, d, and e is not larger than 6; or R⁶ and R⁷ together forms a -CH=CH-CH=N-, -CH=CH-N=CH-, -CH=N-CH=CH-, -N=CH-CH=CH-, or =N-S-N= bridge;

R⁴ is hydrogen; amino; nitro; cyano; halogen; acylamino; phenyl which may be substituted one or more times with alkyl, amino, halogen, or CF₃; aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁴ together with R' forms a -(NR¹¹)_m-C(=O)-, -(NR¹¹)_m-CHOH-, or a -N=C- bridge wherein R¹¹ is hydrogen or alkyl, and m is 1;

R¹¹ is phenyl which may be substituted one or more times with alkyl, halogen, or CF₃; benzimidazolyl which may be substituted one or more times with alkyl, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃, amino, nitro, cyano, acylamino, trifluoromethyl; alkoxy; or acyl; provided that at least one of R⁶ and R⁷ is other than hydrogen.

2. A compound of claim 1 wherein R⁴ is hydrogen and R³ is




wherein R¹¹ is pyridyl.

3. A compound of claim 1, which is

1-[3-(3-pyridyl)-phenyl]-5-methylalldoximo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(2-furanyl)-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or
 4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-*ab*][1,4]benzodiazepine,
 or a pharmaceutically acceptable salt thereof.


4. A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

5. The use of a compound having the formula:



or a pharmaceutically acceptable salt thereof
wherein

R³ is



wherein

X is N; or C-R' wherein R' is hydrogen or together with R⁴ forms a $-(NR^{111})_m-C(=O)-$, $-(NR^{111})_m-CHOH-$, or a $-N=C-$ bridge wherein R¹¹¹ is hydrogen or alkyl and m is 0 or 1;

one of A, B, C, and D is N and the others are CH;

one of E, F, G, and K is N-R'' wherein R'' is hydrogen or alkyl and the others of E, F, G, and K are CH₂;

R⁶ and R⁷ are independently hydrogen; halogen; amino; nitro; cyano; acylamino; trifluoromethyl; alkyl; alkoxy; COO-alkyl; acyl; CH=NOH, CH=NO-alkyl; CH=N-NH-(C=O)-NH₂; phenyl which may be substituted one or more times with alkyl, nitro, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁶ and R⁷ together forms a $(CH_2)_a-(Z)_b-(C=Y)_c-(Z')_d-(CH_2)_e$ bridge wherein each of Z and Z' independently are O, S, or NR''' wherein R''' is hydrogen or alkyl, Y is O or H₂, a and e are each independently 0, 1, 2, or 3 and b, c, and d are each independently 0 or 1 provided that the sum of a, b, c, d, and e is not larger than 6; or R⁶ and R⁷ together forms a $-CH=CH-CH=N-$, $-CH=CH-N=CH-$, $-CH=N-CH=CH-$, $-N=CH-CH=CH-$, or $=N-S-N=$ bridge;


R⁴ is hydrogen; amino; nitro; cyano; halogen; acylamino; phenyl which may be substituted one or more times with alkyl, amino, halogen, or CF₃; aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃; or R⁴ together with R' forms a $-(NR^{111})_m-C(=O)-$, $-(NR^{111})_m-CHOH-$, or a $-N=C-$ bridge wherein R¹¹¹ is hydrogen or alkyl, and m is 1;

R¹¹ is halogen; amino; nitro; cyano; COO-alkyl; acylamino; CF₃; alkyl; alkoxy; morpholinyl; phenyl which may be substituted one or more times with alkyl, halogen, or CF₃; benzimidazolyl which may be substituted one or more times with alkyl, halogen, or CF₃; or aryl which may be substituted one or more times with alkyl, phenyl, halogen, or CF₃, amino, nitro, cyano, acylamino, trifluoromethyl; alkoxy; or acyl, for the manufacture of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which is responsive to modulation of the benzodiazepine receptor of the central nervous system of such a living animal body, including a human.

6. The use of a compound of claim 2 for the manufacture of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which is responsive to modulation of the benzodiazepine receptor of the central nervous system of such a living animal body, including a human.
7. The use of a compound as in claim 5 for the manufacture of a medicament for the treatment of anxiety, sleep disorders, memory disorders, epilepsy or any other convulsive disorder of a living animal body, including a human.
8. The use as in claim 5, wherein the compound employed is
1-[3-(3-pyridyl)-phenyl]-5-methylaloximo-benzimidazole,
1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,
1-[3-(3-pyridyl)-phenyl]-5-(2-furanyl)-benzimidazole,

1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or
 4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-*ab*][1,4]benzodiazepine,
 or a pharmaceutically-acceptable addition salt thereof.

9. A method of preparing a compound of claim 1, comprising the step of reacting a compound having the formula



wherein R³, R⁴, R⁶ and R⁷ have the meanings set forth in claim 1, with formic acid or a reactive derivative thereof.

10. A method of claim 9 wherein

1-[3-(3-pyridyl)-phenyl]-5-methylalldoximo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(2-furanyl)-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-6-iodo-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-methyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-imidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-iodo-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-*t*-butyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-*i*-propyl-benzimidazole,
 1-[3-(1-(2-methylimidazolyl))-phenyl]-5-phenyl-benzimidazole,
 1-[3-(1-benzimidazolyl)-phenyl]-5-trifluoromethyl-benzimidazole,
 1-[3-(3-pyridyl)-phenyl]-5-(3-furanyl)-benzimidazole, or
 4-trifluoromethyl-6,7-dihydro-6-methyl-7-oxo-benzimidazo-[3,4-*ab*][1,4]benzodiazepine,
 or a pharmaceutically-acceptable addition salt thereof, is prepared.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 94 61 0012
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CLS)
P, X	EP-A-0 563 001 (NEUROSEARCH A/S) 29 September 1993 * the whole document *	1-10	A61K31/415 A61K31/44 C07D401/10 C07D405/14 C07D403/10 C07D235/06 C07D487/06 C07D471/06 C07D405/00 C07D413/00 C07D401/00 C07D513/04
A	EP-A-0 520 200 (NEUROSEARCH A/S) * the whole document *	1-10	
A	US-A-5 158 969 (S.-P. OLESEN ET AL.) * the whole document *	1-10	
X	CHEMICAL ABSTRACTS, vol. 100, no. 17, 23 April 1984, Columbus, Ohio, US; abstract no. 139029t, F.A. HUSSEIN ET AL '1-(Para or meta-cinnamoylphenyl)-5-nitrobenzimidazoles' page 644 ; * abstract * * see also attached computer print-out * & IRAQI J. SCI. vol. 23, no. 3 , 1982 pages 293 - 309 --- -/--	1,9,10	
			TECHNICAL FIELDS SEARCHED (Int.CLS)
			C07D A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 27 June 1994	Examiner Allard, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C07)

European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 94 61 0012

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	TETRAHEDRON [®] vol. 31 , September 1975 , OXFORD GB pages 2163 - 2170 K.T. POTTS ET AL. 'Aromatic substitution by N-arylhydroxylamines-I' * page 2166, formula 16 * -----	1,9,10	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)

EPO FORM 1503 (01/82) (P4/C10)



EP 94 61 0012

-C-

INCOMPLETE SEARCH

Claims searched completely: 2,3,6,8,10

Claims searched incompletely: 1,4,5,7,9

An exhaustive search for claims 1,4,5,7 and 9 would have to cover such a large number of subdivisions of the systematically arranged documentation that such search would not be economically justified. The search has consequently been limited to the subdivisions of the documentation which are supported by examples in the description, see Guidelines for Examination in the EPO, B-III, 2.1 and 3.7.



1